The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines

Journal of Pathology

Volumn 218, Issue 4, 2009, Pages 467-477

  Prystowsky, Michael B ^a   Adomako, Alfred ^a   Smith, Richard V ^a   Kawachi, Nicole ^a   McKimpson, Wendy ^a   Atadja, Peter ^b   Chen, Quan ^a   Schlecht, Nicolas F ^a   Parish, Joanna L ^c   Childs, Geoffrey ^a   Belbin, Thomas J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Cell cycle arrest; Cell death; Gene expression microarray; Head and neck squamous cell carcinoma; Histone deacetylase inhibitor

Indexed keywords

CENTROMERE PROTEIN A; COMPLEMENTARY DNA; PANOBINOSTAT; PROTEIN P21; RNA; SURVIVIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CENP F GENE; CENP M GENE; CENTROMERE; CHROMOSOME SEGREGATION; CLINICAL ARTICLE; CONTROLLED STUDY; DDX11 GENE; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GENE TARGETING; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MITOSIS INHIBITION; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATOR GENE; SISTER CHROMATID; SMC2L1 GENE; SQUAMOUS CELL CARCINOMA; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL DEATH; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; G2 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 67650898226     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2554     Document Type: Article

References (102)

1. Belbin TJ, Schlecht NF, Smith RV, Adrien LR, Kawachi N, Brandwein-Gensler M, et al. Site-specific molecular signatures predict aggressive disease in HNSCC. Head Neck Pathol 2008;2:243-256.
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-1900.
3. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972;29:1446-1449.
4. NCCN Head and Neck Panel. National Comprehensive Cancer Network Practice Guidelines in Oncology - Head Neck Cancers. Report, 22 May 2008.
5. Bourhis J, Calais G, Lapeyre M, Tortochaux J, Alfonsi M, Sire C, et al. Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). Semin Oncol 2004;31:822-826.
6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
7. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006;116(9):( Pt 2 Suppl 111): 1-3.
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
9. Beitler JJ, Garg M, Owen RP, Sarta C, Smith RV, Yaparpalvi R. High-dose-rate brachytherapy plus neck dissection for nodal disease. Head Neck 2008;30:933-938.
10. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944.
11. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-1952.
12. Hake SB, Xiao A, Allis CD. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 2004;90:761-769.
13. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer. Part I: Covalent histone modifications. Trends Mol Med 2007;13:363-372.
14. Pogo BG, Pogo AO, Allfrey VG, Mirsky AE. Changing patterns of histone acetylation and RNA synthesis in regeneration of the liver. Proc Natl Acad Sci U S A 1968;59:1337-1344.
15. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-45.
16. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008;615:261-298.
17. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14:4500-4510.
18. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007;29:163-188.
19. Schlecht NF, Burk RD, Adrien L, Dunne A, Kawachi N, Sarta C, et al. Gene expression profiles in HPV-infected head and neck cancer. J Pathol 2007;213:283-293.
20. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-1501.
21. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
22. Lee TH, Solomon MJ, Mumby MC, Kirschner MW. INH, a negative regulator of MPF, is a form of protein phosphatase 2A. Cell 1991;64:415-423.
23. Schreiber-Agus N, Meng Y, Hoang T, Hou H, Chen K, Greenberg R, et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998;393:483-487.
24. Liang H, Samanta S, Nagarajan L. SSBP2, a candidate tumor suppressor gene, induces growth arrest and differentiation of myeloid leukemia cells. Oncogene 2005;24:2625-2634.
25. Yasuda M, Han JW, Dionne CA, Boyd JM, Chinnadurai G. BNIP3alpha: a human homolog of mitochondrial proapoptotic protein BNIP3. Cancer Res 1999;59:533-537.
26. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997;89:175-184.
27. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 2000;16:653-699.
28. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M, et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 1994;8:465-480.
29. Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 1994;14:2077-2086.
30. Thommes P, Fett R, Schray B, Burkhart R, Barnes M, Kennedy C, et al. Properties of the nuclear P1 protein, a mammalian homologue of the yeast Mcm3 replication protein. Nucleic Acids Res 1992;20:1069-1074.
31. Yin MJ, Shao L, Voehringer D, Smeal T, Jallal B. The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis. J Biol Chem 2003;278:52454-52460.
32. Heald R, McLoughlin M, McKeon F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 1993;74:463-474.
33. Chun AC, Jin DY. Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J Biol Chem 2003;278:37439-37450.
34. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003;100:5789-5794.
35. Jost M, Huggett TM, Kari C, Boise LH, Rodeck U. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem 2001;276:6320-6326.
36. Yuan ZQ, Kim D, Kaneko S, Sussman M, Bokoch GM, Kruh GD, et al. ArgBP2gamma interacts with Akt and p21-activated kinase-1 and promotes cell survival. J Biol Chem 2005;280:21483-21490.
37. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biol 2005;7:591-600.
38. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999;147:545-558.
39. Saha P, Thome KC, Yamaguchi R, Hou Z, Weremowicz S, Dutta A. The human homolog of Saccharomyces cerevisiae CDC45. J Biol Chem 1998;273:18205-18209.
40. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y, et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 2003;11:997-1008.
41. Frouin I, Montecucco A, Biamonti G, Hubscher U, Spadari S, Maga G. Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins. EMBO J 2002;21:2485-2495.
42. Huggins CF, Chafin DR, Aoyagi S, Henricksen LA, Bambara RA, Hayes JJ. Flap endonuclease 1 efficiently cleaves base excision repair and DNA replication intermediates assembled into nucleosomes. Mol Cell 2002;10:1201- 1211.
43. Sugasawa K, Ng JM, Masutani C, Maekawa T, Uchida A, van der Spek PJ, et al. Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity. Mol Cell Biol 1997;17:6924-6931.
44. Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A 1996;93:13629-13634.
45. Henry-Mowatt J, Jackson D, Masson JY, Johnson PA, Clements PM, Benson FE, et al. XRCC3 and Rad51 modulate replication fork progression on damaged vertebrate chromosomes. Mol Cell 2003;11:1109-1117.
46. Unsal-Kacmaz K, Chastain PD, Qu PP, Minoo P, Cordeiro-Stone M, Sancar A, et al. The human Tim/Tipin complex coordinates an Intra-S checkpoint response to UV that slows replication fork displacement. Mol Cell Biol 2007;27:3131-3142.
47. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 2000;14:1448-1459.
48. Zhu X, Mancini MA, Chang KH, Liu CY, Chen CF, Shan B, et al. Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. Mol Cell Biol 1995;15:5017-5029.
49. Liu D, Ding X, Du J, Cai X, Huang Y, Ward T, et al. Human NUF2 interacts with centromere-associated protein E and is essential for a stable spindle microtubule-kinetochore attachment. J Biol Chem 2007;282:21415-21424.
50. Ono T, Fang Y, Spector DL, Hirano T. Spatial and temporal regulation of condensins I and II in mitotic chromosome assembly in human cells. Mol Biol Cell 2004;15:3296-3308.
51. Wang H, Hu X, Ding X, Dou Z, Yang Z, Shaw AW, et al. Human Zwint-1 specifies localization of Zeste White 10 to kinetochores and is essential for mitotic checkpoint signaling. J Biol Chem 2004;279:54590-54598.
52. Ogryzko VV, Brinkmann E, Howard BH, Pastan I, Brinkmann U. Antisense inhibition of CAS, the human homologue of the yeast chromosome segregation gene CSE1, interferes with mitosis in HeLa cells. Biochemistry 1997;36:9493-9500.
53. Rankin S, Ayad NG, Kirschner MW. Sororin, a substrate of the anaphase-promoting complex, is required for sister chromatid cohesion in vertebrates. Mol Cell 2005;18:185-200.
54. Amann J, Kidd VJ, Lahti JM. Characterization of putative human homologues of the yeast chromosome transmission fidelity gene, CHL1. J Biol Chem 1997;272:3823-3832.
55. Parish JL, Rosa J, Wang X, Lahti JM, Doxsey SJ, Androphy EJ. The DNA helicase ChlR1 is required for sister chromatid cohesion in mammalian cells. J Cell Sci 2006;119:4857-4865.
56. Li H, Cuenin C, Murr R, Wang ZQ, Herceg Z. HAT cofactor Trrap regulates the mitotic checkpoint by modulation of Mad1 and Mad2 expression. EMBO J 2004;23:4824-4834.
57. Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL, et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002;62:1662-1668.
58. Martin-Lluesma S, Stucke VM, Nigg EA. Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2. Science 2002;297:2267-2270.
59. Xie S, Xie B, Lee MY, Dai W. Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 2005;24:277-286.
60. Lin YT, Chen Y, Wu G, Lee WH. Hec1 sequentially recruits Zwint-1 and ZW10 to kinetochores for faithful chromosome segregation and spindle checkpoint control. Oncogene 2006;25:6901-6914.
61. Famulski JK, Vos L, Sun X, Chan G. Stable hZW10 kinetochore residency, mediated by hZwint-1 interaction, is essential for the mitotic checkpoint. J Cell Biol 2008;180:507-520.
62. Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T, Baum LG. A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4. Mol Cell Biol 1994;14:3350-3363.
63. Fang G, Yu H, Kirschner MW. Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G1. Mol Cell 1998;2:163-171.
64. Gassmann R, Carvalho A, Henzing AJ, Ruchaud S, Hudson DF, Honda R, et al. Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J Cell Biol 2004;166:179-191.
65. Zhu C, Zhao J, Bibikova M, Leverson JD, Bossy-Wetzel E, Fan JB, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005;16:3187-3199.
66. Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C, et al. RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol Cell Biol 2006;26:3853-3863.
67. Mollinari C, Kleman JP, Jiang W, Schoehn G, Hunter T, Margolis RL. PRC1 is a microtubule binding and bundling protein essential to maintain the mitotic spindle midzone. J Cell Biol 2002;157:1175-1186.
68. Gruss OJ, Wittmann M, Yokoyama H, Pepperkok R, Kufer T, Sillje H, et al. Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells. Nature Cell Biol 2002;4:871-879.
69. McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 2004;68:1139-1144.
70. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304.
71. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003;4:13-18.
72. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-5552.
73. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev Cancer 2006;6:38-51.
74. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-4635.
75. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26:81-87.
76. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 2008;99:689-694.
77. Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008;112:2896-2905.
78. Shin HJ, Baek KH, Jeon AH, Kim SJ, Jang KL, Sung YC, et al. Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 2003;22:3853-3858.
79. Inoue A, Li T, Roby SK, Valentine MB, Inoue M, Boyd K, et al. Loss of ChlR1 helicase in mouse causes lethality due to the accumulation of aneuploid cells generated by cohesion defects and placental malformation. Cell Cycle 2007;6:1646-1654.
80. Yang Z, Guo J, Chen Q, Ding C, Du J, Zhu X. Silencing mitosin induces misaligned chromosomes, premature chromosome decondensation before anaphase onset, and mitotic cell death. Mol Cell Biol 2005;25:4062-4074.
81. Holt SV, Vergnolle MA, Hussein D, Wozniak MJ, Allan VJ, Taylor SS. Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. J Cell Sci 2005;118:4889-4900.
82. Regnier V, Vagnarelli P, Fukagawa T, Zerjal T, Burns E, Trouche D, et al. CENP-A is required for accurate chromosome segregation and sustained kinetochore association of BubR1. Mol Cell Biol 2005;25:3967-3981.
83. Chan GK, Liu ST, Yen TJ. Kinetochore structure and function. Trends Cell Biol 2005;15:589-598.
84. Sironi L, Melixetian M, Faretta M, Prosperini E, Helin K, Musacchio A. Mad2 binding to Mad1 and Cdc20, rather than oligomerization, is required for the spindle checkpoint. EMBO J 2001;20:6371-6382.
85. Hwang LH, Lau LF, Smith DL, Mistrot CA, Hardwick KG, Hwang ES, et al. Budding yeast Cdc20: a target of the spindle checkpoint. Science 1998;279:1041-1044.
86. Rieder CL, Schultz A, Cole R, Sluder G. Anaphase onset in vertebrate somatic cells is controlled by a checkpoint that monitors sister kinetochore attachment to the spindle. J Cell Biol 1994;127:1301-1310.
87. Liao CF, Luo SF, Shen TY, Lin CH, Chien JT, Du SY, et al. CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs. BMB Rep (Korea) 2008;41:210-216.
88. Geley S, Kramer E, Gieffers C, Gannon J, Peters JM, Hunt T. Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol 2001;153:137-148.
89. Yang X, Kovalenko D, Nadeau RJ, Harkins LK, Mitchell J, Zubanova O, et al. Sef interacts with TAK1 and mediates JNK activation and apoptosis. J Biol Chem 2004;279:38099-38102.
90. Song Y, Ailenberg M, Silverman M. Human munc13 is a diacylglycerol receptor that induces apoptosis and may contribute to renal cell injury in hyperglycemia. Mol Biol Cell 1999;10:1609-1619.
91. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, et al. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 2002;62:7264-7272.
92. Ueda K, Arakawa H, Nakamura Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 2003;22:5586-5591.
93. Cabodi S, Calautti E, Talora C, Kuroki T, Stein PL, Dotto GP. A PKC-eta/Fyn-dependent pathway leading to keratinocyte growth arrest and differentiation. Mol Cell 2000;6:1121-1129.
94. Tago K, Nakamura T, Nishita M, Hyodo J, Nagai S, Murata Y, et al. Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein. Genes Dev 2000;14:1741-1749.
95. Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH. SUMO-1/Ubc9 promotes nuclear accumulation and metabolic stability of tumor suppressor Smad4. J Biol Chem 2003;278:31043-31048.
96. Buschmann T, Lerner D, Lee CG, Ronai Z. The Mdm-2 amino terminus is required for Mdm2 binding and SUMO-1 conjugation by the E2 SUMO-1 conjugating enzyme Ubc9. J Biol Chem 2001;276:40389-40395.
97. Segre JA, Bauer C, Fuchs E. Klf4 is a transcription factor required for establishing the barrier function of the skin. Nature Genet 1999;22:356-360.
98. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 2006;66:7589-7597.
99. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-1063.
100. Gottfried Y, Rotem A, Lotan R, Steller H, Larisch S. The mitochondrial ARTS protein promotes apoptosis through targeting XIAP. EMBO J 2004;23:1627-1635.
101. Lotan R, Rotem A, Gonen H, Finberg JP, Kemeny S, Steller H, et al. Regulation of the proapoptotic ARTS protein by ubiquitin-mediated degradation. J Biol Chem 2005;280:25802-25810.
102. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.